Immuron (IMRN) said Thursday it plans to launch a phase 2 trial of IMM-529 in individuals with Clostridioides difficile infection after it received favorable feedback from the US Food and Drug Administration on the pre-investigational new drug information package for IMM-529.
The phase 2 trial will come after the drugmaker's expected filing of an investigational new drug application for IMM-529 in H1 of 2025, Immuron said.
Clostridioides difficile is a bacterium that causes diarrhea and inflammation of the colon.
Shares of Immuron fell 9.7% in recent trading.
Price: 2.42, Change: -0.26, Percent Change: -9.70
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments